Abstract
Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis through binding to its specific receptors, which mainly occurs to VEGF receptor 2 (VEGFR-2), a kinase insert domain-containing receptor. Therefore, the disruption of VEGFR-2 signaling provides a promising therapeutic approach for the treatment of cancer by inhibiting abnormal or tumorinduced angiogenesis. To explore this potential, we expressed the catalytic domain of VEGFR- 2 (VEGFR-2-CD) as a soluble active kinase in Escherichia coli. The recombinant protein was purified and the VEGFR-2-CD activity was investigated. The obtained VEGFR-2-CD showed autophosphorylation activity and phosphate transfer activity comparable to the commercial enzyme. Furthermore, the IC50 value of known VEGFR-2 inhibitor was determined using the purified VEGFR-2-CD. These results indicated a possibility for functional and economical VEGFR-2-CD expression in E. coli to use for inhibitor screening.
Original language | English (US) |
---|---|
Pages (from-to) | 1227-1233 |
Number of pages | 7 |
Journal | Journal of Microbiology and Biotechnology |
Volume | 25 |
Issue number | 8 |
DOIs | |
State | Published - Apr 23 2015 |
Bibliographical note
Publisher Copyright:© 2015, by The Korean Society for Microbiology and Biotechnology.
Keywords
- Anticancer drug screening
- Catalytic domain
- E. coli expression system
- Inhibitors
- Soluble expression
- Vascular endothelial growth factor receptor 2